About C3J Therapeutics
C3J Therapeutics is a Healthcare company based in Los Angeles (United States) founded in 2006. Pathogen-specific antimicrobials are developed for microbial dysbiosis diseases. C3J Therapeutics has raised $214.5 million across 9 funding rounds from investors including HHS, Renaissance Acquisition Holdings and Delta Dental. The company has 60 employees. C3J Therapeutics offers products and services including Bacteriophages, Synthetic Phage Platform, AP-PA02, and AP-PA03. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is C3J Therapeutics, Inc. Its competitors include Inflammatix, GenMark Diagnostics and T2 Biosystems; 3 of its 3 listed competitors have raised funding.
Company details
C3J Therapeutics was established in 2006 in Los Angeles, United States, with operations centered on the biotechnology sector. Specifically targeted antimicrobial peptides (STAMPs) are advanced for treating and preventing conditions linked to microbial dysbiosis. Key pipeline elements include C16G2, advanced to Phase 2 for dental caries prevention, and CD17-DL, in Phase 1 for C. difficile infection management. A PCR-based diagnostic for S. mutans detection is also in development.
- Headquarters Los Angeles, United States
- Employees 60
- SectorsHealthcare
- Email••••••••
- Website c3jtherapeutics.com
- Social LinkedIn
- Legal Name C3j Therapeutics, Inc.
- Total Equity Funding$214.5M (USD)
in 9 rounds
- Latest Funding Round$19M (USD), Series D
Dec 2016
- InvestorsHHS
& 2 more
- Employee Count60
Products & Services of C3J Therapeutics
C3J Therapeutics offers a comprehensive portfolio of products and services, including Bacteriophages, Synthetic Phage Platform, AP-PA02, and AP-PA03.
Technology for targeting and destroying bacterial pathogens.
System for developing engineered phages against infections.
Therapeutic for specific bacterial infections and resistance.
Advanced phage therapy for combating resistant bacteria.
Funding Insights of C3J Therapeutics
C3J Therapeutics has successfully raised a total of $214.5M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $19 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $214.5M
- Total Rounds 9
- Last Round Series D — $19M
- First Round $99,999
(Aug 2009)
- Investors Count 3
All 9 funding rounds of C3J Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $19M | Series D | – | – | – |
| Dec 2015 | $567,839 | Grant | – | – | |
| Mar 2014 | $60.5M | Series D | – | Renaissance Acquisition Holdings | |
| Mar 2014 | $60M | Series D | – | – | – |
| Feb 2012 | $30M | Series B | – | – | – |
| Feb 2012 | $30M | Private Equity Round | – | – | – |
| Apr 2010 | $100,000 | Grant | – | – | |
| Jan 2010 | $15M | Series A | – | – | – |
| Aug 2009 | $99,999 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in C3J Therapeutics
C3J Therapeutics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Renaissance Acquisition Holdings and Delta Dental.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Online gaming and gambling platform | 2010 | renaissanceah.com | Lake Forest, United States | |
Dental insurance plans are offered by Delta Dental nationwide. | deltadental.com | United States |
Investor details for C3J Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of C3J Therapeutics
3 dated milestones of C3J Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded C3J Therapeutics is founded.
- Funding First funding round of $100K.
- Funding Latest funding round, Series D, of $19.0M.
Competitors of C3J Therapeutics
C3J Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, GenMark Diagnostics and T2 Biosystems.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| t2biosystems.com | 2006 | Lexington, United States | $454.3M | 166 | Miniaturized MRI platforms for clinical diagnostics are developed. |
Detailed competitors of C3J Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as C3J Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about C3j Therapeutics
Complete news archive for C3J Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about C3J Therapeutics
C3J Therapeutics was founded in 2006 and raised its 1st funding round 3 years after it was founded.
C3J Therapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
C3J Therapeutics is a funded company, having raised a total of $214.5M across 9 funding rounds to date. The company's 1st funding round was a Grant of $100K, raised on Aug 2009.
C3J Therapeutics has 60 employees.
C3J Therapeutics was established in 2006 in Los Angeles, United States, with operations centered on the biotechnology sector. Specifically targeted antimicrobial peptides (STAMPs) are advanced for treating and preventing conditions linked to microbial dysbiosis. Key pipeline elements include C16G2, advanced to Phase 2 for dental caries prevention, and CD17-DL, in Phase 1 for C. difficile infection management. A PCR-based diagnostic for S. mutans detection is also in development.
C3J Therapeutics's top competitors include Inflammatix, GenMark Diagnostics and T2 Biosystems.
C3J Therapeutics offers Bacteriophages, Synthetic Phage Platform, AP-PA02, and AP-PA03.
C3J Therapeutics has 3 investors. Key investors include HHS, Renaissance Acquisition Holdings, and Delta Dental.
C3J Therapeutics operates through C3j Therapeutics, Inc..